BidaskClub upgraded shares of Calithera Biosciences (NASDAQ:CALA) from a strong sell rating to a sell rating in a report released on Friday morning.

CALA has been the subject of several other reports. William Blair initiated coverage on shares of Calithera Biosciences in a research note on Thursday, October 5th. They issued an outperform rating for the company. Zacks Investment Research upgraded shares of Calithera Biosciences from a hold rating to a buy rating and set a $19.00 target price for the company in a research note on Monday, November 6th. Finally, ValuEngine downgraded shares of Calithera Biosciences from a hold rating to a sell rating in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $15.17.

Shares of Calithera Biosciences (NASDAQ:CALA) traded down $0.15 on Friday, reaching $8.45. 383,919 shares of the company’s stock traded hands, compared to its average volume of 990,832. The firm has a market capitalization of $294.55, a P/E ratio of -8.54 and a beta of 2.89. Calithera Biosciences has a 52 week low of $3.15 and a 52 week high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The firm had revenue of $7.20 million during the quarter, compared to analyst estimates of $6.02 million. analysts anticipate that Calithera Biosciences will post -0.77 EPS for the current year.

In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total value of $9,008,640.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 16.30% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC raised its holdings in shares of Calithera Biosciences by 85.8% in the second quarter. FMR LLC now owns 2,717,090 shares of the biotechnology company’s stock worth $40,349,000 after buying an additional 1,254,900 shares during the last quarter. State Street Corp raised its holdings in shares of Calithera Biosciences by 5,802.1% in the second quarter. State Street Corp now owns 1,304,375 shares of the biotechnology company’s stock worth $19,370,000 after buying an additional 1,282,275 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Calithera Biosciences by 29.7% in the second quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock worth $17,813,000 after buying an additional 274,510 shares during the last quarter. Lord Abbett & CO. LLC raised its holdings in shares of Calithera Biosciences by 65.5% in the second quarter. Lord Abbett & CO. LLC now owns 497,811 shares of the biotechnology company’s stock worth $7,392,000 after buying an additional 197,055 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Calithera Biosciences by 272.8% in the third quarter. American Century Companies Inc. now owns 424,752 shares of the biotechnology company’s stock worth $6,690,000 after buying an additional 310,806 shares during the last quarter. 72.19% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/23/calithera-biosciences-cala-upgraded-to-sell-at-bidaskclub.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Stock Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related stocks with our FREE daily email newsletter.